Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo controlled, parallel and multiple dose study provided
safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and
BMS-224818 in subjects with RA